[Form 4] Surgery Partners, Inc. Insider Trading Activity
Surgery Partners' Chief Financial Officer, David T. Doherty, reported a sale of common stock on 08/08/2025. The Form 4 shows 47,491 shares sold at a weighted average price of $23.39, and lists 103,377 shares held following the transaction, all shown as direct ownership.
The filing includes an explanatory note that the reported price is a weighted average and identifies Jennifer Baldock as the attorney-in-fact who signed the form on 08/08/2025. The reporting person鈥檚 address is shown as Surgery Partners' Brentwood, TN office and the form indicates the filer is an officer serving as Chief Financial Officer.
Il Chief Financial Officer di Surgery Partners, David T. Doherty, ha dichiarato la vendita di azioni ordinarie il 08/08/2025. Il modulo Form 4 indica la vendita di 47.491 azioni a un prezzo medio ponderato di $23,39 e riporta 103.377 azioni detenute dopo la transazione, tutte in propriet脿 diretta.
La comunicazione specifica che il prezzo riportato 猫 un valore medio ponderato e identifica Jennifer Baldock come procuratrice che ha firmato il modulo il 08/08/2025. L'indirizzo del dichiarante 猫 indicato come l'ufficio di Surgery Partners a Brentwood, TN, e il modulo segnala che il dichiarante ricopre la carica di Chief Financial Officer.
El Director Financiero de Surgery Partners, David T. Doherty, inform贸 la venta de acciones ordinarias el 08/08/2025. El Formulario 4 muestra la venta de 47.491 acciones a un precio medio ponderado de $23,39, y indica que quedaron 103.377 acciones en su posesi贸n tras la operaci贸n, todas en propiedad directa.
La presentaci贸n a帽ade una nota explicativa que aclara que el precio informado es un promedio ponderado e identifica a Jennifer Baldock como apoderada que firm贸 el formulario el 08/08/2025. La direcci贸n del declarante figura como la oficina de Surgery Partners en Brentwood, TN, y el formulario se帽ala que el firmante ocupa el cargo de Chief Financial Officer.
Surgery Partners鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� David T. Doherty電� 2025雲� 8鞗� 8鞚� 氤错喌欤茧ゼ 毵る弰頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. Form 4鞐愲姅 47,491欤� 毵る弰臧赌 欤茧嫻 韽夑窢臧赌 $23.39搿� 響滌嫓霅橃柎 鞛堨溂氅�, 瓯半灅 頉� 103,377欤�毳� 氤挫湢頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堦碃 氇憪 歆侅爲 靻岇湢搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 氤搓碃霅� 臧赌瓴╈澊 臧赌欷� 韽夑窢鞛勳潉 靹る獏頃橂姅 氅旊臧赌 韽暔霅橃柎 鞛堨溂氅�, Jennifer Baldock臧赌 2025雲� 8鞗� 8鞚� 頃措嫻 鞏戩嫕鞚� 靹滊獏頃� 雽�毽澑鞙茧 頇曥澑霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潣 欤检唽電� Surgery Partners鞚� 韰岆劋鞁滌＜ 敫岆爩韸胳毎霌�(Brentwood) 靷靻岆 響滌嫓霅橃柎 鞛堨溂氅�, 鞏戩嫕鞐愲姅 鞁犼碃鞚胳澊 斓滉碃鞛毂呾瀯鞛�(Chief Financial Officer) 歆侅眳鞚� 毵￡碃 鞛堨潓鞚� 鞝侅嫓頃橁碃 鞛堨姷雼堧嫟.
Le directeur financier de Surgery Partners, David T. Doherty, a d茅clar茅 la vente d'actions ordinaires le 08/08/2025. Le formulaire Form 4 indique la cession de 47 491 actions 脿 un prix moyen pond茅r茅 de 23,39 $, et mentionne 103 377 actions d茅tenues apr猫s la transaction, toutes en propri茅t茅 directe.
Le d茅p么t comporte une note explicative pr茅cisant que le prix d茅clar茅 est une moyenne pond茅r茅e et identifie Jennifer Baldock comme mandataire ayant sign茅 le formulaire le 08/08/2025. L'adresse de la personne d茅clarant est indiqu茅e comme le bureau de Surgery Partners 脿 Brentwood (TN) et le formulaire pr茅cise que le d茅clarant exerce la fonction de Chief Financial Officer.
Der Chief Financial Officer von Surgery Partners, David T. Doherty, meldete am 08.08.2025 den Verkauf von Stammaktien. Im Form 4 sind 47.491 verkaufte Aktien zu einem gewichteten Durchschnittspreis von $23,39 verzeichnet; nach der Transaktion werden 103.377 Aktien im Besitz aufgef眉hrt, alle als direkte Eigentumsanteile.
Die Einreichung enth盲lt einen Hinweis, dass der angegebene Preis ein gewichteter Durchschnitt ist, und nennt Jennifer Baldock als Bevollm盲chtigte, die das Formular am 08.08.2025 unterschrieb. Die Adresse der meldepflichtigen Person wird als das B眉ro von Surgery Partners in Brentwood, TN, angegeben, und das Formular weist darauf hin, dass der Melder als Chief Financial Officer t盲tig ist.
- Transaction fully disclosed with transaction date, share count, weighted average price and post-transaction holdings
- Explanatory note clarifies the reported price is a weighted average and the form is signed by an attorney-in-fact
- Officer sale of 47,491 shares reported, reducing direct holdings to 103,377 shares
- Filing provides no stated rationale for the sale or indication it was executed under a disclosed trading plan
Insights
TL;DR: CFO sold 47,491 SGRY shares at $23.39, leaving 103,377 shares; transaction disclosed but lacks contextual rationale.
The Form 4 documents a direct sale of 47,491 shares executed on 08/08/2025 at a weighted average price of $23.39. After the sale the reporting person holds 103,377 shares directly. From a trading-impact perspective, an insider sale of this size is notable because it materially changes immediate insider holdings and could attract investor attention; however, the filing provides no explanation for the sale or indication it was part of a pre-arranged plan, so market interpretation will depend on external context not present in the filing.
TL;DR: Form 4 appears properly executed with weighted-average pricing note and attorney-in-fact signature; disclosure is complete though context is limited.
The filing contains the required elements: reporter identity and role as Chief Financial Officer, transaction date, security type, number of shares sold, a weighted average price disclosure, post-transaction beneficial ownership, and a signature executed by an attorney-in-fact on 08/08/2025. The explanatory note clarifies the price reporting method. The document does not provide the reporter's rationale or indicate whether the sale was under a trading plan, so governance conclusions about intent cannot be drawn solely from this filing.
Il Chief Financial Officer di Surgery Partners, David T. Doherty, ha dichiarato la vendita di azioni ordinarie il 08/08/2025. Il modulo Form 4 indica la vendita di 47.491 azioni a un prezzo medio ponderato di $23,39 e riporta 103.377 azioni detenute dopo la transazione, tutte in propriet脿 diretta.
La comunicazione specifica che il prezzo riportato 猫 un valore medio ponderato e identifica Jennifer Baldock come procuratrice che ha firmato il modulo il 08/08/2025. L'indirizzo del dichiarante 猫 indicato come l'ufficio di Surgery Partners a Brentwood, TN, e il modulo segnala che il dichiarante ricopre la carica di Chief Financial Officer.
El Director Financiero de Surgery Partners, David T. Doherty, inform贸 la venta de acciones ordinarias el 08/08/2025. El Formulario 4 muestra la venta de 47.491 acciones a un precio medio ponderado de $23,39, y indica que quedaron 103.377 acciones en su posesi贸n tras la operaci贸n, todas en propiedad directa.
La presentaci贸n a帽ade una nota explicativa que aclara que el precio informado es un promedio ponderado e identifica a Jennifer Baldock como apoderada que firm贸 el formulario el 08/08/2025. La direcci贸n del declarante figura como la oficina de Surgery Partners en Brentwood, TN, y el formulario se帽ala que el firmante ocupa el cargo de Chief Financial Officer.
Surgery Partners鞚� 斓滉碃鞛毂呾瀯鞛�(CFO)鞚� David T. Doherty電� 2025雲� 8鞗� 8鞚� 氤错喌欤茧ゼ 毵る弰頄堧嫟瓿� 鞁犼碃頄堨姷雼堧嫟. Form 4鞐愲姅 47,491欤� 毵る弰臧赌 欤茧嫻 韽夑窢臧赌 $23.39搿� 響滌嫓霅橃柎 鞛堨溂氅�, 瓯半灅 頉� 103,377欤�毳� 氤挫湢頃� 瓴冹溂搿� 旮办灛霅橃柎 鞛堦碃 氇憪 歆侅爲 靻岇湢搿� 響滌嫓霅橃柎 鞛堨姷雼堧嫟.
鞁犼碃靹滌棎電� 氤搓碃霅� 臧赌瓴╈澊 臧赌欷� 韽夑窢鞛勳潉 靹る獏頃橂姅 氅旊臧赌 韽暔霅橃柎 鞛堨溂氅�, Jennifer Baldock臧赌 2025雲� 8鞗� 8鞚� 頃措嫻 鞏戩嫕鞚� 靹滊獏頃� 雽�毽澑鞙茧 頇曥澑霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃鞚胳潣 欤检唽電� Surgery Partners鞚� 韰岆劋鞁滌＜ 敫岆爩韸胳毎霌�(Brentwood) 靷靻岆 響滌嫓霅橃柎 鞛堨溂氅�, 鞏戩嫕鞐愲姅 鞁犼碃鞚胳澊 斓滉碃鞛毂呾瀯鞛�(Chief Financial Officer) 歆侅眳鞚� 毵￡碃 鞛堨潓鞚� 鞝侅嫓頃橁碃 鞛堨姷雼堧嫟.
Le directeur financier de Surgery Partners, David T. Doherty, a d茅clar茅 la vente d'actions ordinaires le 08/08/2025. Le formulaire Form 4 indique la cession de 47 491 actions 脿 un prix moyen pond茅r茅 de 23,39 $, et mentionne 103 377 actions d茅tenues apr猫s la transaction, toutes en propri茅t茅 directe.
Le d茅p么t comporte une note explicative pr茅cisant que le prix d茅clar茅 est une moyenne pond茅r茅e et identifie Jennifer Baldock comme mandataire ayant sign茅 le formulaire le 08/08/2025. L'adresse de la personne d茅clarant est indiqu茅e comme le bureau de Surgery Partners 脿 Brentwood (TN) et le formulaire pr茅cise que le d茅clarant exerce la fonction de Chief Financial Officer.
Der Chief Financial Officer von Surgery Partners, David T. Doherty, meldete am 08.08.2025 den Verkauf von Stammaktien. Im Form 4 sind 47.491 verkaufte Aktien zu einem gewichteten Durchschnittspreis von $23,39 verzeichnet; nach der Transaktion werden 103.377 Aktien im Besitz aufgef眉hrt, alle als direkte Eigentumsanteile.
Die Einreichung enth盲lt einen Hinweis, dass der angegebene Preis ein gewichteter Durchschnitt ist, und nennt Jennifer Baldock als Bevollm盲chtigte, die das Formular am 08.08.2025 unterschrieb. Die Adresse der meldepflichtigen Person wird als das B眉ro von Surgery Partners in Brentwood, TN, angegeben, und das Formular weist darauf hin, dass der Melder als Chief Financial Officer t盲tig ist.
FAQ
What did the Surgery Partners (SGRY) Form 4 report?
When was the transaction executed according to the filing?
What price was reported for the SGRY shares sold?
Who signed the Form 4 for the reporting person?
What is the reporting person鈥檚 role at Surgery Partners?
